An HHS Office of Inspector General report says the FDA does not approve 96% of new generic drugs reviewed during their first cycle because they contain chemistry deficiencies. The document, which examines generic drug reviews for 2006, says the agency exceeded the 180-day review requirement for 46% of original applications.
From the August 01, 2008 Issue of MM+M - Medical Marketing and Media
